NTC acquires part of Novartis’ ophthalmic portfolio

Italy-based pharmaceutical group NTC has acquired part of Novartis’ ophthalmic portfolio for the Spanish, Portuguese, Italian and Polish markets. The acquired products include  Colircusi Gentadexa (aminoglycoside), Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside), Oftalmolosa Cusi Erythromycin (macrolide), Oftalmolosa Cusi Aureomycin (tetracycline) and Oftacilox (fluoroquinolone). The parties did not provide the financial details of the transaction.

NTC is headquartered in Milan and has distributors and partners in over 100 countries in the world, generating 70% of its revenues in EMEA regions. The group is part of private equity Wise SGR’s company portfolio. The operation has been financed with a mix of equity and debt.

(Source: Wise SGR)